

**Company Overview**

Siva Therapeutics is developing a safe and effective cancer treatment termed **Targeted Hyperthermia™ (THT)**, which generates therapeutic heat within solid tumors using **SivaRods™** gold nanorods and a **SivaLum™** infrared light device. THT has multiple beneficial effects on tumors, and it is more selective than chemotherapy, less destructive than radiation, and without the risks of surgery. Siva has raised over \$2.4 million to date, over \$2 million through grants and \$400,000 through angel investors, in addition to founder contributions. The company is currently raising \$2.0 million in Seed financing, which will enable Siva to complete large animal preclinical studies, to validate immune-oncology responses in large animals, and to file for an Investigational Device Exemption (IDE) from the FDA.

**Need in Colorectal Cancer Treatment**

Siva’s initial clinical target is first-line treatment for early to stage 3 **colorectal cancer (CRC)**. While the 5-year survival rate for CRC is relatively good (~65%,) patient quality of life is poor, resulting in a large unmet need. CRC tends to be localized through early stage 4, making it ideal for local interventional treatment. THT for CRC will be a minimally invasive outpatient procedure that addresses an underserved patient segment.

**Initial Market**


There are approximately 148,000 new cases of colorectal cancer in the US every year, and 53,000 deaths. The US market is currently estimated to be **\$9 billion** with an 8% CAGR, the **addressable market for THT is projected at \$4 billion**. Additional markets will follow.

**Product Technology**

THT is an **interventional oncology** approach which employs the systemic injection of polymer-coated gold nanorods (SivaRods) into the patient and illumination of the affected region with a near infrared light device (SivaLum). The SivaRods concentrate in tumors, absorb the infrared light, and convert it into therapeutic heat which emanates from **within** the tumor mass. Heat stimulates the immune system, shrinks tumors, and enhances drug efficacy.

**Strong Preclinical Data**

THT has very strong preclinical efficacy data, both as a monotherapy and in combination with a leading cancer drug. **THT stand-alone treatment is significantly more effective than the drug monotherapy:** all animals on drug alone were dead by 30 days after the study



began. Combination treatment with both THT and drug (images below), yields outstanding results: 66% of the animals survived and thrived out to 95 days post-treatment, the end of the study, with no evidence of residual cancer. The preclinical safety profile is excellent.

**Management Team**

**50 years of combined biotech/life science/med device experience; with 5 previous cash-flow positive companies with products to market; a surgical services company from startup to acquisition; 12x return for early investors; oncology lead molecule identified, partnered and in the clinic; and a drug discovery product line from concept to \$26MM P&L; acquisition for multiple of revenues.**

- CEO: Len Pagliaro, PhD – ThermoFisher Scientific, BioImage A/S, Cerep Inc. (Eurofins)
- COO: Colin Shepherd, PhD, MBA – PhylloTech, AimsBio
- Cofounder & Counsel: Steve Kregstein, JD – ClearVision, Sound Surgical

**Current Raise and Use of Funds**

**Siva is raising a \$2,000,000 Seed round – Milestones:**

1. Pre-clinical large animal immuno-modulation data
2. Large animal data for preferential uptake of SivaRods in tumors
3. Large animal validation of catheter-based light delivery to tumors
4. Regulatory feedback on endpoints and patient numbers for device approval
5. Prepare for first in human studies

